Good News on Early Breast Cancer: Herceptin Treatment Can Be Shortened
A large, new study shows that the treatment regimen, typically recommended for a year, can be just as effective at 6 months, reducing serious side effects and costs. (Source: NYT Health)
Source: NYT Health - May 16, 2018 Category: Consumer Health News Authors: DENISE GRADY Tags: Breast Cancer Herceptin (Drug) Genentech Inc Earl, Helena M side effects Source Type: news

Breast Cancer Patients May Shorten Herceptin Regimen: Study
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 16, 2018 Category: Cancer & Oncology Tags: Gynecology, Oncology, News, Source Type: news

Roche breast cancer drug treatment time can be halved - study
(Reuters) - Treating early stage breast cancer patients for just six months with Roche's Herceptin works as well as the current 12-month regimen, researchers who conducted a large clinical trial said on Wednesday. (Source: Reuters: Health)
Source: Reuters: Health - May 16, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Shorter drug treatment OK for many breast cancer patients
New research suggests that many women with a common and aggressive form of breast cancer that is treated with Herceptin can get by with six months of the drug instead of the usual 12 (Source: ABC News: Health)
Source: ABC News: Health - May 16, 2018 Category: Consumer Health News Tags: Health Source Type: news

For Women With Early Breast Cancer, Herceptin Treatment Can Be Much Shorter
A large, new study shows that the treatment regimen, typically recommended for a year, can be just as effective at 6 months, reducing serious side effects and costs. (Source: NYT Health)
Source: NYT Health - May 16, 2018 Category: Consumer Health News Authors: DENISE GRADY Tags: Breast Cancer Herceptin (Drug) American Society of Clinical Oncology Cambridge University side effects Genentech Inc Source Type: news

Mathematical Modeling May Guide Cancer Treatment & #039;Holidays & #039;
A Moffitt team suggests mathematical modeling may guide the optimal cancer treatment dosing approach better than MTD. (Source: CancerNetwork)
Source: CancerNetwork - May 16, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: Breast Cancer Melanoma News Source Type: news

Multi-epitope T-cell Vaccine Shows Promise in Ovarian, Breast Cancer
TPIV200 stimulates T cells to attack ovarian and triple negative breast tumor cells that over-express the folate receptor alpha protein. (Source: CancerNetwork)
Source: CancerNetwork - May 16, 2018 Category: Cancer & Oncology Authors: By John Schieszer Tags: Breast Cancer Immuno Oncology News Ovarian Cancer Source Type: news

Breast Cancer Patients May Shorten Herceptin Regimen: Study
WEDNESDAY, May 16, 2018 -- For years, the drug Herceptin has helped women with an aggressive form of breast cancer beat the disease. But there's one downside: In a minority of cases, the drug can trigger heart damage. Now, a new study finds that... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 16, 2018 Category: General Medicine Source Type: news

Medical News Today: Is breast asymmetry linked to breast cancer?
Many women have slight differences in the size or shape of their breasts. Breast asymmetry is usually not a cause for concern, though substantial asymmetry in the size or density of breasts may suggest an increased risk of breast cancer. A mammogram can look for abnormalities and diagnose the cause of breast asymmetry. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 16, 2018 Category: Consumer Health News Tags: Women's Health / Gynecology Source Type: news

Shorter trastuzumab treatment for HER2+ breast cancer can be as effective, with fewer cardiac side-effects
(American Society of Clinical Oncology) A phase III randomized clinical trial of 4,088 women with HER2-positive, early-stage breast cancer found that taking trastuzumab (Herceptin) for 6 months was non-inferior to the current standard of 12 months. The disease-free survival rate at four years was 89.4 percent with 6 months of therapy and 89.8 percent with 12 months of therapy. In addition, only 4 percent of women in the 6-month arm stopped trastuzumab early because of cardiac problems, compared with 8 percent in the 12-month arm. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 16, 2018 Category: International Medicine & Public Health Source Type: news

Diagnosing breast cancer with an imaging pill
(American Chemical Society) For women, mammograms are a sometimes uncomfortable, but necessary, annual ritual. But this procedure doesn't always provide accurate results, and it exposes women to X-rays. In a study appearing in ACS' journal Molecular Pharmaceutics, scientists report that they have developed a non-invasive 'disease screening pill' that can make cancerous tumors light up when exposed to near-infrared light in mice without using radiation. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 16, 2018 Category: Cancer & Oncology Source Type: news

A 'dirty bomb' battles cancer metastasis
(Northwestern University) Scientists have developed a new compound that inhibits the spread of cancer cells, which is what makes the disease so lethal. The compound, metarrestin, significantly reduced metastasis by human prostate, pancreatic and breast cancer transplanted into mice. Mice treated with it had fewer metastatic tumors and lived longer than mice that did not receive treatment. Metarrestin is being submitted to the FDA as an investigational drug. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 16, 2018 Category: Cancer & Oncology Source Type: news

Mayo study identifies new potential treatment option for triple negative breast cancer
In this study, Mayo investigators identified that the [...] (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - May 16, 2018 Category: Research Source Type: news

Improving Adherence to Endocrine Therapy in Women With HR-Positive Breast Cancer
Here, we discuss how to improve adherence to endocrine therapy in women with HR-positive breast cancer, as well as the side effects and the reasons for discontinuation. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2018 Category: Cancer & Oncology Authors: Charles L. Shapiro, MD Julia P. Brockway, MD Tags: Breast Cancer Oncology Journal Source Type: news

Mathematical method could automatize, enhance breast cancer diagnosis
Using mathematical models, researchers are developing algorithms and software that could automatize and enhance breast cancer diagnosis. (Source: Health News - UPI.com)
Source: Health News - UPI.com - May 15, 2018 Category: Consumer Health News Source Type: news

CDK4/6 Inhibitors: Game Changers in the Management of Hormone Receptor –Positive Advanced Breast Cancer?
Here, we review the current use of and potential next directions for CDK4/6 inhibitors in the treatment of patients with HR-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2018 Category: Cancer & Oncology Authors: Maria Raquel Nunes, MD Mirat Shah, MD Vered Stearns, MD Tags: Breast Cancer Oncology Journal Review Article Source Type: news

Mathematical methods for diagnosing breast cancer
(Kaunas University of Technology) The team of researchers at Kaunas University of Technology, Lithuania are developing mathematical methods which could help diagnose breast cancer. Applying deep learning method, the researchers are aiming to 'teach' computers to recognize malignant lesions, which would allow at least partially automatize and enhance the accuracy of diagnosing breast cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 15, 2018 Category: Cancer & Oncology Source Type: news

Axillary Ultrasound After Chemotherapy: Mayo Clinic Radio Health Minute
In this Mayo Clinic Radio Health Minute, Dr. Judy Boughey explains how breast cancer care is being tailored to a patients needs. To listen, click the link below. Axillary Ultrasound after Chemo (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 15, 2018 Category: Databases & Libraries Source Type: news

Multigene Sequencing Rapidly Replacing BRCA Tests Multigene Sequencing Rapidly Replacing BRCA Tests
Among women diagnosed with breast cancer, during the past 2 years, the use of multigene testing has risen dramatically, while testing only for BRCA mutations has dropped.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 14, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Breast cancer warning - five symptoms that you should never ignore
BREAST cancer symptoms usually begin with a lump, but all signs should be checked by a doctor. These are the symptoms you should never ignore - is pain one of the symptoms of a deadly tumour? (Source: Daily Express - Health)
Source: Daily Express - Health - May 14, 2018 Category: Consumer Health News Source Type: news

Targeting AXL Could Slow Metastasis in HER2-Positive Breast Cancer
New research has found that expression of AXL is correlated with poor outcomes in patients with HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 14, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer SiteTerms/www.cannabissciencetech.com/News Source Type: news

RoomLab CEO: On Fighting Cancer, A Surprise Pregnancy And Raising Investment
“It was an enormous shock,” says Suzann Bozorgi after a deep breath. The entrepreneur is still new to talking about the breast cancer diagnosis that rocked her life. Yet her mental and physical experience of cancer have directly influenced her the two businesses she's founded. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - May 14, 2018 Category: Pharmaceuticals Authors: Kitty Knowles, Forbes Staff Source Type: news

Study hints at new target to improve immune therapy in triple-negative breast cancer
(University of Colorado Anschutz Medical Campus) University of Colorado Cancer Center study shows that Eya3 may regulate the immune response to a tumor, implying that anti-Eya3 therapies may improve checkpoint inhibitors against triple-negative breast cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 14, 2018 Category: Cancer & Oncology Source Type: news

University of Colorado Cancer Center Study Hints at New Target to...
Eya3 inhibition could be an attractive strategy to increase effectiveness of anti-PD-L1 immunotherapies against triple-negative breast cancer.(PRWeb May 14, 2018)Read the full story at https://www.prweb.com/releases/2018/05/prweb15477653.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 14, 2018 Category: Pharmaceuticals Source Type: news

University of Colorado Cancer Center Study Hints at New Target to...
Eya3 inhibition could be an attractive strategy to increase effectiveness of anti-PD-L1 immunotherapies against triple-negative breast cancer.(PRWeb May 14, 2018)Read the full story at http://www.prweb.com/releases/2018/05/prweb15477653.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 14, 2018 Category: Pharmaceuticals Source Type: news

How Math Can Potentially Reduce Unnecessary Breast Biopsies
The perceived risk of missing a breast cancer diagnosis with imaging studies often leads to unnecessary breast biopsies, according to a new report published in the American Journal of Roentgenology. The authors showed how statistical methods can be used to downgrade the risk classification of breast masses to reduce the need for unnecessary biopsies. Clinicians from San Antonio, TX-based Seno Medical and medical center collaborators from the University of Texas (MD Anderson and U of Texas Health Sciences Center) co-authored the report. The authors studied a statistical calculation known as the negative ...
Source: MDDI - May 11, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Imaging Source Type: news

Breast cancer scare recalls the value of collecting evidence
Research and knowledge are not always enough — people must also notice them (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - May 11, 2018 Category: Pharmaceuticals Source Type: news

Could a pill outperform mammograms?
Researchers have developed an ingestible pill that causes breast tumors to...Read more on AuntMinnie.comRelated Reading: JAMA: Women need to be aware of mammography's harms How serious is the risk of breast cancer overdiagnosis? Is the mammography debate an example of 'fake science'? Women still value mammography's benefits over 'harms' ACR reaffirms support for annual mammography at 40 (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 10, 2018 Category: Radiology Source Type: news

Multigene test increasingly used to assess breast cancer risk
New research suggests women are increasingly foregoing BRCA tests, opting instead for more comprehensive tests that detect mutations in multiple genes. (Source: Health News - UPI.com)
Source: Health News - UPI.com - May 10, 2018 Category: Consumer Health News Source Type: news

Zimbabwe:Breast Cancer Victim Seeks Help
[The Herald] A Harare woman who was diagnosed with breast cancer is appealing for financial assistance to buy medication. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - May 10, 2018 Category: African Health Source Type: news

Medical News Today: Body clock gene may protect against breast cancer
One of the genes that regulate our circadian rhythm might also contribute to the normal development of mammary glands and protect against breast cancer. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 10, 2018 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Bioimpedance Spectroscopy Spots Breast Cancer-related Lymphedema Early Bioimpedance Spectroscopy Spots Breast Cancer-related Lymphedema Early
Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - May 9, 2018 Category: Surgery Tags: Hematology-Oncology News Source Type: news

Breast cancer: Working shifts could impact your chances of developing condition
BREAST cancer research has hinted at a possible new cause of the condition. Disrupting the body clock in women may lead to an increased risk of breast cancer, through activities such as late working the night shift. (Source: Daily Express - Health)
Source: Daily Express - Health - May 9, 2018 Category: Consumer Health News Source Type: news

Breast cancer breakthrough: Working shifts could impact your chances of developin
BREAST cancer research has hinted at a possible new cause of the condition. Disrupting the body clock in women may lead to an increased risk of breast cancer, through activities such as late working the night shift. (Source: Daily Express - Health)
Source: Daily Express - Health - May 9, 2018 Category: Consumer Health News Source Type: news

Maryland woman fired after cancer diagnosis awarded $113K
A Maryland woman who was fired weeks after telling her employer she had breast cancer has been awarded more than $100,000 (Source: ABC News: Health)
Source: ABC News: Health - May 9, 2018 Category: Consumer Health News Tags: Health Source Type: news

Lab Study Shows HER2 Inhibitor Lapatinib Can Induce Cell Proliferation
A laboratory study has found that the HER2 inhibitor lapatinib used to slow HER2-positive breast cancer can actually induce tumor growth in some circumstances. (Source: CancerNetwork)
Source: CancerNetwork - May 8, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer SiteTerms/www.cannabissciencetech.com/News Source Type: news

Could this new pill replace breast screening?
One in three women who undergo breast cancer treatment did not need to; their benign masses were mistaken as cancerous in scans. A new pill by the University of Michigan hopes to change that. (Source: the Mail online | Health)
Source: the Mail online | Health - May 8, 2018 Category: Consumer Health News Source Type: news

Woman devastated to discover her mother has breast cancer
Amberley Kent, 24, from Peterborough, has had an 'awful' past year after undergoing treatment. But she was 'brought back to square one' when her mother Cathy was diagnosed. (Source: the Mail online | Health)
Source: the Mail online | Health - May 8, 2018 Category: Consumer Health News Source Type: news

The Case for Early Screening Mammography The Case for Early Screening Mammography
' Pennywise and pound foolish'screening guidelines put women under 50 at increased risk for delayed breast cancer diagnosis, say researchers.Medscape Medical News (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - May 8, 2018 Category: Radiology Tags: Hematology-Oncology News Source Type: news

OncoSec to combine ImmunoPulse device with Merck ’ s immunotherapy in breast cancer trial
OncoSec Medical (NSDQ:ONCS) expanded its relationship with Merck (NYSE:MRK) today, announcing a deal to combine its ImmunoPulse IL-12 device with Merck’s anti-PD-1 therapy, Keytruda, in a Phase II trial of patients with triple negative breast cancer. The trial is slated to study the drug-device combination in patients with inoperable locally advanced or metastatic cancer who have failed at least one systemic chemotherapy or immunotherapy. Get the full story at our sister site, Drug Delivery Business News. The post OncoSec to combine ImmunoPulse device with Merck’s immunotherapy in breast cancer t...
Source: Mass Device - May 8, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Oncology Pharmaceuticals Wall Street Beat Merck OncoSec Medical Source Type: news

Breast cancer survivors have increased risk of diabetes
A study, published in theJournal of Clinical Oncology, reports that women successfully treated with hormone therapy for breast cancer have a greater risk of developing diabetes. Medpage Today (Source: Society for Endocrinology)
Source: Society for Endocrinology - May 8, 2018 Category: Endocrinology Source Type: news

Mass. imaging spending, use higher than other states
The Massachusetts Health Policy Commission has released a report that finds...Read more on AuntMinnie.comRelated Reading: MITA: MedPAC offers no new proof of imaging overuse ACR 2016: Repeat head CT not always overutilization Is imaging use poised for expansion or contraction? Study links overuse of imaging for prostate, breast cancer Geographic variations don't necessarily signify imaging overuse (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 8, 2018 Category: Radiology Source Type: news

ONC201 kills breast cancer cells in vitro by targeting mitochondria
(Rapamycin Press) 'Our work identifies a novel mechanism of ONC201 cytotoxicity that is based on the disruption of mitochondrial function, leading to ATP depletion and cell death in cancer cells that are dependent on mitochondrial respiration. Our study also suggests that cancer cells that are dependent on glycolysis will be resistant to ONC201' Dr. Stanley Lipkowitz, Chief, Women's Malignancies Branch, NCI. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 8, 2018 Category: Cancer & Oncology Source Type: news

Texas A & M study links breast cancer to the body's internal clock
(Texas A&M University) For years, doctors have associated the BRCA1 and BRCA2 gene mutations with an increased risk of breast cancer. But researchers at Texas A&M University have now identified another gene that may have an impact on breast cancer --associated with the body's circadian rhythm. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 8, 2018 Category: Cancer & Oncology Source Type: news

Genetic Test Criteria Often Miss Breast Cancer Risk
(MedPage Today) -- Similar cancer-linked mutations in patients who did or did not met test criteria (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - May 7, 2018 Category: Hematology Source Type: news

Impact of mass breast cancer screening has been overrated | Letter
It has not been shown to affect women ’s life expectancy overall, but does increase invasive interventions, saySusan Bewley, Nick RossandMargaret McCartney of HealthWatchThe announcement that thousands missed out on mammography tests caused distress to many women and their families (Report, 4 May). The implication was that they now risked premature death from cancer. In fact, as many experts have been pointing out, mass screening for breast cancer has not been shown to have any impact on women ’s life expectancy overall – but it does increase invasive interventions like mastectomy. This is why Prof Mike B...
Source: Guardian Unlimited Science - May 7, 2018 Category: Science Authors: Letters Tags: Breast cancer Health Society Cancer research Medical research Science Women Life and style UK news Jeremy Hunt Politics Source Type: news

Poor Prognosis for Interval Breast Cancer After Negative Mammo
Odds of poor prognosis after mammography with negative results higher for younger women (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 7, 2018 Category: Cancer & Oncology Tags: Gynecology, Oncology, Radiology, Journal, Source Type: news

Poor Prognosis for Interval Breast Cancer After Negative Mammo
MONDAY, May 7, 2018 -- The likelihood of having breast cancer with a poor prognosis is increased for cancer diagnosed after a screening mammography with negative results, according to a research letter published online May 3 in JAMA Oncology. Anne... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 7, 2018 Category: Pharmaceuticals Source Type: news

High Insurance Deductibles Lead Breast Cancer Patients to Delay Care: Study
Title: High Insurance Deductibles Lead Breast Cancer Patients to Delay Care: StudyCategory: Health NewsCreated: 5/4/2018 12:00:00 AMLast Editorial Review: 5/7/2018 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - May 7, 2018 Category: Cancer & Oncology Source Type: news

ASBrS: Regular mammo screening = less-invasive treatment
Regular breast cancer screening, particularly in younger women, translates...Read more on AuntMinnie.comRelated Reading: ASBrS: No, we're not overtreating DCIS ASBrS: 50% of women under 45 at elevated breast cancer risk ASBrS: For node-positive breast cancer, radiotherapy is best ASBrS: Radiotherapy after mastectomy may not be beneficial ASBrS: RF ablation shows promise; thermography not so much (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 7, 2018 Category: Radiology Source Type: news